复星财富控股:艾美疫苗(6660.HK)创新产品驱动价值重估 首予“买入”评级目标价11港元

格隆汇资讯
14 Feb

复星财富控股发研报指,综合考虑艾美疫苗(6660.HK)强大的研发实力、技术领先优势以及国际市场拓展潜力,鉴于其强劲的增长前景和具有吸引力的估值,首次覆盖并给予其“买入”评级,目标价11港元,较2025年2月12日收盘价存在100%的上涨空间。研报认为,艾美疫苗作为中国疫苗行业的领军企业,凭借全产业链布局和卓越的研发、生产及商业化能力,持续巩固市场领先地位。公司现已构建起多元化的产品矩阵,拥有五大...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10